OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+8%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$104M
AUM Growth
+$104M
(+0.34%)
Cap. Flow
-$8.68M
Cap. Flow
% of AUM
-8.35%
Top 10 Holdings %
Top 10 Hldgs %
46.09%
Holding
50
New
7
Increased
20
Reduced
12
Closed
3
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$4.72M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$4.12M |
| 3 |
iShares Biotechnology ETF
IBB
|
$2.12M |
| 4 |
Pacira BioSciences
PCRX
|
$1.71M |
| 5 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$891K |
Top Sells
| 1 |
iShares Russell 2000 ETF
IWM
|
$23M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
$3.11M |
| 3 |
IQVIA
IQV
|
$1.52M |
| 4 |
Hologic
HOLX
|
$571K |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$332K |
Sector Composition
| 1 | Healthcare | 72.89% |
| 2 | Real Estate | 0.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR S&P Biotech ETF
XBI
$5.07B
| $8.62M | 4.83% | 130,000 +71,143 | +121% | +$4.72M |
|
|
2
iShares Biotechnology ETF
IBB
$5.6B
| $7.24M | 4.06% | 25,000 +7,319 | +41% | +$2.12M |
|
3
Merck
MRK
$210B
| $5.22M | 2.93% | 83,700 | – | – |
|
|
4
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $4.12M | 2.31% | +85,000 | New | +$4.12M |
|
5
Bristol-Myers Squibb
BMY
$96B
| $4.08M | 2.29% | 75,686 +3,983 | +6% | +$215K |
|
6
AstraZeneca
AZN
$248B
| $3.94M | 2.21% | 120,000 +11,437 | +11% | +$376K |
|
7
Alkermes
ALKS
$4.78B
| $3.84M | 2.15% | 81,677 -1,181 | -1% | -$55.5K |
|
8
Pfizer
PFE
$141B
| $3.8M | 2.13% | 112,300 | – | – |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.67M | 2.06% | 67,953 -6,140 | -8% | -$332K |
|
10
Biogen
BIIB
$19.4B
| $3.35M | 1.88% | 10,704 +1,662 | +18% | +$520K |
|
11
Illumina
ILMN
$15.8B
| $3.34M | 1.87% | 18,400 -341 | -2% | -$62K |
|
12
Incyte
INCY
$16.5B
| $3.27M | 1.83% | 34,626 -611 | -2% | -$57.6K |
|
13
Amgen
AMGN
$155B
| $3.06M | 1.71% | 18,322 -297 | -2% | -$49.5K |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.05M | 1.71% | 45,064 +1,380 | +3% | +$93.5K |
|
15
Nektar Therapeutics
NKTR
$568M
| $3.03M | 1.7% | 176,611 -1,920 | -1% | -$33K |
|
|
QGENF
16
DELISTED
QIAGEN NV
QGENF
| $3.03M | 1.7% | 110,565 +4,814 | +5% | +$132K |
|
17
Regeneron Pharmaceuticals
REGN
$61.5B
| $3.02M | 1.69% | 7,512 +279 | +4% | +$112K |
|
18
Mettler-Toledo International
MTD
$26.8B
| $3.02M | 1.69% | 7,188 | – | – |
|
|
ALXN
19
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.01M | 1.69% | 24,571 +7,270 | +42% | +$891K |
|
20
Agios Pharmaceuticals
AGIO
$2.19B
| $2.89M | 1.62% | 54,692 +11,397 | +26% | +$602K |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.84M | 1.59% | 30,639 +1,724 | +6% | +$160K |
|
|
CELG
22
DELISTED
Celgene Corp
CELG
| $2.81M | 1.57% | 26,859 +3,927 | +17% | +$411K |
|
23
Vertex Pharmaceuticals
VRTX
$100B
| $2.8M | 1.57% | 32,141 +1,893 | +6% | +$165K |
|
24
Ionis Pharmaceuticals
IONS
$6.79B
| $2.8M | 1.57% | 76,439 +5,571 | +8% | +$204K |
|
25
GSK
GSK
$79.9B
| $2.59M | 1.45% | 60,000 +10,000 | +20% | +$431K |
|